Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). D...

Source: BMC Cancer - December 3, 2018 Category: Cancer & Oncology Authors: Wan-Ling Tan, Quan Sing Ng, Cindy Lim, Eng Huat Tan, Chee Keong Toh, Mei-Kim Ang, Ravindran Kanesvaran, Amit Jain, Daniel S. W. Tan and Darren Wan-Teck Lim Tags: Research article Source Type: research